This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Crucial Conversations in Oncology Nursing: Management Considerations for the AML Patient

Crucial Conversations in Oncology Nursing: Management Considerations for the AML Patient



Time to Complete

1 hour


September 14, 2018


September 14, 2019
Add to Queue

Maximum Credits

1.00 / CNE Contact Hour (0.75 pharmacotherapeutic contact hours)

Accredited Provider

Provided by American Academy of CME, Inc.

Commercial Supporter

This activity is supported through an education grant from Pfizer.

Program Description

The landscape of AML treatment is evolving and newer targeted agents may improve outcomes for selected subgroups of patients. Oncology nursing professionals provide disease and treatment information, manage adverse effects, and offer emotional support. Knowledge of the key management issues for patients with AML is critical in fulfilling this role. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention is critical in order to reduce the potential for serious adverse events and complications.

Intended Audience

Oncology Nurses, Nurse Practitioners, and Nurse Navigators

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review recently approved agents for patients with newly diagnosed and relapsed AML and their implications for patient selection and nursing care
  • Evaluate patients with AML receiving treatment with recently approved agents in order to identify early indications of adverse events and implement appropriate interventions
  • Outline key education points for the patient and family/caregiver to prevent infection, identify signs of bleeding, and perform other assessments to improve early identification and management of adverse events

Conflict Of Interest Disclosure Policy

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.


Laura Zitella, MS, RN, ACNP-BC, AOCN
Hematology/Oncology Nurse Practitioner
Clinical Associate Professor
University of California
San Francisco, CA

Ms. Zitella discloses the following:
Advisory Board – for scientific information: Abbvie, Amgen, Array BioPharma Inc, Astra Zeneca, Gilead Sciences
Shareholder: Kite Pharmaceuticals

Accredited Provider Disclosures

American Academy of CME
Wendy Gloffke, PhD; Natalie Kirkwood, RN, BSN, JD (Lead Nurse Planner); Paul J Miniter, MS; John JD Juchniewicz, MCIS, CHCP have no relevant financial relationships with commercial interests.




CNE Contact Hour(s)

Accreditation Statement

American Academy of CME, Inc, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

American Academy of CME, Inc., designates this educational activity for 1.00 contact hour (pharmacotherapeutic contact hours 0.75).

California: Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.00 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents not indicated by the FDA. Faculty have been asked to disclose off-label and/or investigational uses if they are mentioned.


The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, or American Nurses Credentialing Center’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Before using any medication, learners should consult primary references and full prescribing information. Please refer to official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

If you have questions or comments about this activity, contact


Privacy Policy

For more information about the American Academy of CME privacy policy, please access

myCME privacy policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue